Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

被引:69
作者
Baumann, F
Bjeljac, M
Kollias, SS
Baumert, BG
Brandner, S
Rousson, V
Yonekawa, Y
Bernays, RL [1 ]
机构
[1] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Inst Neuroradiol, CH-8091 Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland
[4] Univ Zurich Hosp, Dept Neuropathol, CH-8091 Zurich, Switzerland
[5] Univ Zurich, Dept Biostat, Zurich, Switzerland
关键词
antiangiogenic therapy; brain; chemotherapy; glioblastoma multiforme; survival; temozolomide; thalidomide; treatment;
D O I
10.1023/B:NEON.0000021803.01170.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Glioblastoma multiforme (GBM) may potentially be responsive to antiangiogenic therapies as these tumors are highly vascularized and overexpress angiogenic factors. Thalidomide exhibits antiangiogenic activity and may provide additive or synergistic antitumor effects when given concurrently with temozolomide, an alkylating agent. To further evaluate this new concept of combining an antiangiogenic with an alkylating agent, efficacy and tolerability of thalidomide alone and in combination with temozolomide were explored in a single-institution, nonrandomized open-label phase II study. Patients and methods: Forty-four patients with GBMs, who received thalidomide for a period of at least three months, were evaluated for survival, time to tumor progression (TTP), and side effects. Microsurgical tumor extirpation and radiotherapy preceded chemotherapy. Nineteen patients (43%) received thalidomide only (T), and 25 patients (57%) had a combined chemotherapy of thalidomide and temozolomide (TT). Median thalidomide dosage was 200 mg/day. Median temozolomide dosage was 200 mg/m(2)/day for five days, in monthly cycles. Neuroradiological outcomes were assessed by a semiquantitative grading system. Results: Median survival was 103 weeks (95% CI, 65-141 weeks) for TT-patients and 63 weeks (95% CI, 49-77 weeks) for T-patients (p < 0.01). Median TTP for the TT-group was 36 weeks (95% CI, 20-52 weeks) and 17 weeks (95% CI, 13-21 weeks) for the T-group (p < 0.06). Neuroradiologically, 14 patients (56%) of the TT-group and six (32%) of the T-group had evidence of stable disease on at least two successive neuroradiological follow-ups. Progressive disease was found in nine patients (36%) of the TT-group and in 13 (68%) of the T-group. In two patients (8%) of the TT-group, a response with tumor regression was found. Thalidomide and concurrent temozolomide were safe and well tolerated with mild to moderate toxicities. Conclusions: The combination of thalidomide and temozolomide in the treatment of GBM appears to be more effective than that of thalidomide alone with respect to survival, TTP, and neuroradiological documentation of progression, stable disease or response. Further concurrent prospective studies of these agents in a larger group of patients with GBM will be required to establish the soundness of these intriguing observations.
引用
收藏
页码:191 / 200
页数:10
相关论文
共 32 条
[1]   Thalidomide in the treatment of cancer [J].
Adlard, JW .
ANTI-CANCER DRUGS, 2000, 11 (10) :787-791
[2]  
Afra D, 2002, LANCET, V359, P1011
[3]  
[Anonymous], 2000, Pathology and Genetics of Tumours of the Nervous System
[4]   Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study [J].
Brandes, AA ;
Scelzi, E ;
Salmistraro, G ;
Ermani, M ;
Carollo, C ;
Berti, F ;
Zampieri, P ;
Baiocchi, C ;
Fiorentino, MV .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (10) :1592-1596
[5]   THE ACCURACY OF VOLUMETRIC MEASUREMENT OF HIGH-GRADE GLIOMAS [J].
CHISHOLM, RA ;
STENNING, S ;
HAWKINS, TD .
CLINICAL RADIOLOGY, 1989, 40 (01) :17-21
[6]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[7]   Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas [J].
Fine, HA ;
Figg, WD ;
Jaeckle, K ;
Wen, PY ;
Kyritsis, AP ;
Loeffler, JS ;
Levin, VA ;
Black, PM ;
Kaplan, R ;
Pluda, JM ;
Yung, WKA .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :708-715
[8]  
Flageul B, 2000, ANN DERMATOL VENER, V127, P171
[9]  
FORSTING M, 1993, AM J NEURORADIOL, V14, P77
[10]  
Khan RB, 2002, NEURO-ONCOLOGY, V4, P39, DOI 10.1093/neuonc/4.1.39